Posted by Michael Wonder on 05 Feb 2018
Acerus Pharma’s Natesto to be listed for public reimbursement in Quebec
1 February 2018 - Acerus Pharmaceuticals Corporation today announced that it has received notice from Quebec’s National Institute for Excellence in Health and Social Services (INESSS) of a positive recommendation to the Health Minister for the inclusion of Natesto on the list of medications of the Régie de l’assurance maladie du Québec.
This recommendation takes effect on 1 February 2018.
“One of our key aims at Acerus is to make innovative products like Natesto accessible to all Canadian patients in need of treatment,” said Luc Mainville, Interim Chief Executive Officer of Acerus. “The positive INESSS decision immediately gives patients in Quebec access to another important option to manage the symptoms of hypogonadism.”
